Agenus is a biotechnology company engaged in the development of treatments for cancers and infectious diseases. The company’s focus is on immunotherapeutic products based on strong platform technologies, and it has multiple product candidates advancing through the clinic; this includes several product candidates that have advanced into late-stage clinical trials through corporate partners. For more information, visit the company’s Web site at www.agenusbio.com.